Valdizán-Usón, J RCánovas-Martínez, ALucas-Taracena, M T deDíaz-Atienza, FEddy-Ives, L SFernández-Jaén, AFernández-Pérez, MGarcía-Giral, MGarcía-Magán, PGarraus-Oneca, MIdiazábal-Alecha, M ALópez-Benito, MLorenzo-Sanz, GMartínez-Antón, JMartínez-Granero, M AMontañés-Rada, FMulas-Delgado, FOchando-Perales, GOrtega-García, EPelaz-Antolín, ARamos-Quiroga, J ARuiz-Sanz, F CVaquerizo-Madrid, JYusta-Izquierdo, A2014-01-082014-01-082013-02-08Valdizán-Usón JR, Cánovas-Martínez A, De Lucas-Taracena MT, Díaz-Atienza F, Eddy-Ives LS, Fernández-Jaén A, et al. Response to methylphenidate by adult and pediatric patients with attention-deficit/hyperactivity disorder: the Spanish multicenter DIHANA study. Neuropsychiatr Dis Trea. 2013; 9:218http://hdl.handle.net/10668/1447Journal Article;BACKGROUND The purpose of this multicenter Spanish study was to evaluate the response to immediate-release methylphenidate by children and adults diagnosed with attention-deficit/hyperactivity disorder (ADHD), as well as to obtain information on current therapy patterns and safety characteristics. METHODS This multicenter, observational, retrospective, noninterventional study included 730 patients aged 4-65 years with a diagnosis of ADHD. Information was obtained based on a review of medical records for the years 2002-2006 in sequential order. RESULTS The ADHD predominantly inattentive subtype affected 29.7% of patients, ADHD predominantly hyperactive-impulsive was found in 5.2%, and the combined subtype in 65.1%. Overall, a significant lower Clinical Global Impression (CGI) score and mean number of DSM-IV TR (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision) symptoms by subtype were found after one year of treatment with immediate-release methylphenidate; CGI decreased from 4.51 to 1.69, symptoms of inattention from 7.90 to 4.34, symptoms of hyperactivity from 6.73 to 3.39, and combined subtype symptoms from 14.62 to 7.7. Satisfaction with immediate-release methylphenidate after one year was evaluated as "very satisfied" or "satisfied" by 86.90% of the sample; 25.75% of all patients reported at least one adverse effect. At the end of the study, 41.47% of all the patients treated with immediate-release methylphenidate were still receiving it, with a mean time of 3.80 years on therapy. CONCLUSION Good efficacy and safety results were found for immediate-release methylphenidate in patients with ADHD.enAttention deficit hyperactivity disorderADHDPharmacologic treatmentMethylphenidateSatisfactionMetilfenidatoTrastorno por Déficit de Atención con HiperactividadEstudios Multicéntricos como AsuntoEspañaNiñoAdultoMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Carboxylic Acids::Acids, Carbocyclic::Phenylacetates::MethylphenidateMedical Subject Headings::Psychiatry and Psychology::Mental Disorders::Mental Disorders Diagnosed in Childhood::Attention Deficit and Disruptive Behavior Disorders::Attention Deficit Disorder with HyperactivityMedical Subject Headings::Geographicals::Geographic Locations::Europe::SpainMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Multicenter Studies as TopicMedical Subject Headings::Named Groups::Persons::Age Groups::AdultMedical Subject Headings::Named Groups::Persons::Age Groups::Childresearch article23430373open access10.2147/NDT.S358361176-6328PMC3573811